The FDA approved a new treatment for women with sexual desire disorder, medically known as Hypo-Active Sexual Desire Disorder (HSDD). The pill, nicknamed the Female Viagra, will only be available through healthcare providers. HSDD is characterized through low sexual preference that reasons marked distress or interpersonal issue and isn’t due to a co-existing medical or psychiatric situation, troubles inside the courting, or the effects of a medication or other drug substance. HSDD is received while it develops in a patient who formerly had no troubles with sexual desire. HSDD is generalized when it occurs irrespective of the sort of sexual hobby, the state of affairs or the sexual accomplice. This female sexual desire treatment had been under scrutiny for many years prior by the FDA due to the number of side effect by its previous male version of the drug; but which is now irrelevant.
Here is the press release by the FDA:
Saleamp Design August 20th, 2015